Evidence-informed pharmacology monograph, updated 10 November 2026. For medical education; individual management requires current product labeling and qualified clinical assessment.
Overview and chemistry
Procainamide is a class IA antiarrhythmic used in selected monitored settings for atrial or ventricular tachyarrhythmias. It is p-amino-N-[2-(diethylamino)ethyl]benzamide, structurally related to but distinct from the ester local anesthetic procaine. The former description of a ‘3,4-diaminobenzamide’ core and ‘phase-0 repolarization’ was chemically and electrophysiologically inaccurate [1,2].
Receptor and ion-channel effects
Procainamide inhibits voltage-gated fast sodium currents, slowing phase-0 depolarization and conduction through atrial, His-Purkinje and ventricular tissue; it also prolongs refractoriness and the QT interval. Its active metabolite N-acetylprocainamide (NAPA) contributes more prominently to repolarization prolongation through class III-like effects. Both drug and metabolite can contribute to torsades risk [1].
Pharmacokinetics and genetic variability
Procainamide is metabolized to NAPA by N-acetyltransferase, with interindividual differences in acetylation rate. Both parent drug and NAPA undergo renal elimination, so kidney dysfunction can prolong exposure and necessitate dosing changes. Plasma concentration monitoring, where available, and ECG interpretation should complement kidney function and clinical hemodynamics [1,2].
Clinical uses and precautions
Intravenous procainamide may be used in selected hemodynamically stable monomorphic wide-complex tachycardia or other electrophysiologically appropriate arrhythmias in a resuscitation-capable environment. Unstable tachycardia generally requires prompt synchronized cardioversion. Avoid use where major hypotension, marked conduction disturbance, significant decompensated heart failure or substantial QT prolongation makes toxicity likely. Arrhythmia subtype and expert protocol determine appropriateness [1,2].
Boxed warning: lupus and blood counts
Current US procainamide injection labeling warns that prolonged therapy often produces positive antinuclear antibodies with or without a drug-induced lupus-like syndrome. Chronic use can also produce serious leukopenia, agranulocytosis and thrombocytopenia. Clinical reassessment and periodic CBC/ANA-related assessment may be required in longer exposure. It is not safe to regard a positive ANA alone as definitive proof of systemic lupus, but benefits and risks must be reviewed [2].
Acute and chronic toxicity
Rapid IV administration can cause severe hypotension, QRS widening, AV block, QT prolongation, torsades or ventricular fibrillation. Continuous ECG and blood pressure monitoring are essential during IV therapy. Other risks include GI effects, rash, hepatic injury and neuropsychiatric symptoms. Interactions with other conduction-slowing or QT-prolonging medicines and electrolyte depletion amplify risk [1,2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- DailyMed. Procainamide hydrochloride injection, USP: prescribing information, including boxed ANA/lupus warning. Updated December 2, 2025. Available from: https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d58751df-cd8b-45a6-8a32-af19e747e23a
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.